Search Results - "Grace S Park"

Early Trends From the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS) by Brunelli, Steven M., MD, MSCE, Monda, Keri L., PhD, Burkart, John M., MD, Gitlin, Matthew, PharmD, Neumann, Peter J., ScD, Park, Grace S., DrPH, Symonian-Silver, Margarita, MD, Yue, Susan, MD, Bradbury, Brian D., DSc, Rubin, Robert J., MD

“…Background Launched in January 2011, the prospective payment system (PPS) for the US Medicare End-Stage Renal Disease Program bundled payment for services…”
Get full text

Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study by CHARLES-SCHOEMAN, Christina, KHANNA, Dinesh, FURST, Daniel E, MCMAHON, Maureen, REDDY, Srinivasa T, FOGELMAN, Alan M, PAULUS, Harold E, PARK, Grace S, GONG, Timothy, ANSELL, Benjamin J

“…OBJECTIVE: Patients with rheumatoid arthritis (RA) have a 2-3-fold increased risk of myocardial infarction. Recent work suggests that plasma high density…”
Get full text

Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial by Dinesh Khanna, Daniel E Furst, Philip J Clements, Grace S Park, Ron D Hays, Jeonglim Yoon, Joseph H Korn, Peter A Merkel, Naomi Rothfield, Fredrick M Wigley, Larry W Moreland, Richard Silver, Virginia D Steen, Michael Weisman, Maureen D Mayes, David H Collier, Thomas A Medsger, Jr, James R Seibold, Relaxin Study Group, Scleroderma Clinical Trials Consortium

“…OBJECTIVE: This study compares the responsiveness to change of the Medical Outcomes Study Short Form Health Survey (SF-36), a measure of health related quality…”
Get full text

Reliability, Validity, and Minimally Important Differences of the SF-6D in Systemic Sclerosis by Khanna, Dinesh, Furst, Daniel E., Wong, Weng Kee, Tsevat, Joel, Clements, Philip J., Park, Grace S., Postlethwaite, Arnold E., Ahmed, Mansoor, Ginsburg, Shaari, Hays, Ron D.

“…Objectives To evaluate the reliability and validity and estimate the minimally important difference (MID) for the SF-6D in patients with systemic sclerosis…”
Get full text

Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study by Anstee, Quentin M., Neuschwander-Tetri, Brent A., Wai-Sun Wong, Vincent, Abdelmalek, Manal F., Rodriguez-Araujo, Gerardo, Landgren, Henrik, Park, Grace S., Bedossa, Pierre, Alkhouri, Naim, Tacke, Frank, Sanyal, Arun J.

“…Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb…”
Get full text

Improvement of platysma prominence with onabotulinumtoxinA: Safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial by Fabi, Sabrina, Humphrey, Shannon, Biesman, Brian, George, Rosalyn, LaTowsky, Brenda, Weiss, Robert A., Park, Grace S., Shimoga, Sandhya, Lee, Elisabeth, Jierjian, Edward, Tong, Warren, Hopfinger, René

“…Platysma prominence (PP) refers to the undesirable effects that may occur with platysma muscle contraction. Evaluate safety and efficacy of onabotulinumtoxinA…”
Get full text

Optimizing antimicrobial prophylaxis strategies in acute leukemia patients: Assessing the efficacy of fluconazole by Teran, Nicholas S., Park, Grace S.

“…Background Acute myeloid (AML) and promyelocytic (APL) leukemia patients are at high risk for infection and mortality. While guidance for infection prevention…”
Get full text

A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: Coronary artery calcification in cases and controls by Khurma, Vandana, Meyer, Cris, Park, Grace S., McMahon, Maureen, Lin, Jan, Singh, Ram Raj, Khanna, Dinesh

“…Objective Systemic sclerosis (SSc) is associated with vasculopathy and endothelial cell injury, which could potentially increase the risk of coronary…”
Get full text

"Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Randomized Phase 2 Dose-Ranging Study" by Rohrich, Rod J, Bertucci, Vince, Dayan, Steven, Jones, Derek, Solish, Nowell, Rivers, Jason K, Weiss, Robert, Muhn, Channy Y, Harutunian, Christy, Park, Grace S, Shimoga, Sandhya, Lee, Elisabeth, Tong, Warren

“…With aging, repetitive contraction of the platysma leads to an increase in platysma prominence (PP) characterized by the accentuation of vertical neck bands…”
Get full text

Equivalent Responses to Disease-modifying Antirheumatic Drugs Initiated at Any Time During the First 15 Months After Symptom Onset in Patients with Seropositive Rheumatoid Arthritis by WENG, Haoling H, RANGANATH, Veena K, PAULUS, Harold E, KHANNA, Dinesh, OH, Myungshin, FURST, Daniel E, PARK, Grace S, ELASHOFF, David A, SHARP, John T, GOLD, Richard H, PETER, James B

“…Objective. To evaluate responses by time to initiation of nonbiologic disease-modifying antirheumatic drugs (DMARD) in a DMARD-naive cohort of patients with…”
Get full text

Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset by AMJADI-BEGVAND, Sogol, KHANNA, Dinesh, PARK, Grace S, BULPITT, Ken J, WENG KEE WONG, PAULUS, Harold E

“…OBJECTIVE: A "window of therapeutic opportunity" has been hypothesized to be present in early rheumatoid arthritis (RA). To determine the date of this window,…”
Get full text

Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort by Khanna, Dinesh, Oh, Myungshin, Furst, Daniel E., Ranganath, Veena, Gold, Richard H., Sharp, John T., Park, Grace S., Keystone, Edward C., Paulus, Harold E.

“…Objective To evaluate published proposed definitions of minimal disease activity (MDA) and remission in patients with early rheumatoid arthritis (RA). Methods…”
Get full text

Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis by Francque, Sven M, Hodge, Alexander, Boursier, Jerome, Younes, Ziad H, Rodriguez-Araujo, Gerardo, Park, Grace S, Alkhouri, Naim, Abdelmalek, Manal F

“…Cenicriviroc (CVC) is a novel, orally administered antagonist of chemokine receptor types 2/5 that has demonstrated antifibrotic activity in a phase 2b study…”
Get full text

Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis by Weinblatt, Michael E., Bathon, Joan M., Kremer, Joel M., Fleischmann, Roy M., Schiff, Michael H., Martin, Richard W., Baumgartner, Scott W., Park, Grace S., Mancini, Edward L., Genovese, Mark C.

“…Objective To evaluate the long‐term safety and efficacy of etanercept therapy in rheumatoid arthritis (RA) patients. Methods Adult patients with early RA or…”
Get full text

Defining and characterizing sustained remission in patients with rheumatoid arthritis by Curtis, Jeffrey R., Trivedi, Mona, Haraoui, Boulos, Emery, Paul, Park, Grace S., Collier, David H., Aras, Girish A., Chung, James

“…The objective of this study is to characterize stability and clinical features of patients with rheumatoid arthritis (RA) in sustained remission. Combination…”
Get full text

Correlation of single time-point damage scores with observed progression of radiographic damage during the first 6 years of rheumatoid arthritis by PAULUS, Harold E, MYUNGSHIN OH, SHARP, John T, GOLD, Richard H, WENG KEE WONG, PARK, Grace S, BULPITT, Ken J

“…OBJECTIVE: Aggressive treatment of early rheumatoid arthritis (RA) is recommended to prevent irreversible joint damage. We evaluated the usefulness of single…”
Get full text

Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial by Curtis, Jeffrey R, Yang, Shuo, Chen, Lang, Park, Grace S, Bitman, Bojena, Wang, Brian, Navarro-Millan, Iris, Kavanaugh, Arthur

“…To derive and validate decision trees to categorise rheumatoid arthritis (RA) patients 12 weeks after starting etanercept with or without methotrexate into…”
Get more information

Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment by Paulus, Harold E, Wiesner, Jason, Bulpitt, Ken J, Patnaik, Madhumita, Law, Jacqueline, Park, Grace S, Wong, Weng Kee

“…OBJECTIVE: Autoantibodies observed in patients with rheumatoid arthritis (RA) during clinical trials of immunomodulating agents may cause concern about…”
Get full text

The Disutility of Chronic Gout by Khanna, Dinesh, Ahmed, Mansoor, Yontz, Dustin, Ginsburg, Shaari S., Park, Grace S., Leonard, Anthony, Tsevat, Joel

“…Introduction Gout is a chronic painful inflammatory arthritis. Data regarding the impact of gout on healthrelated quality of life, however, are limited…”
Get full text

Anemia management practice patterns in small dialysis organizations following implementation of the prospective payment system by Burkart, John M, Beaubrun, Anne C, Olson, Kurt A, Park, Grace S, Yue, Susan V, Rubin, Robert J

“…The impact of the United States Prospective Payment System (PPS) "bundle payment system" on anemia management within small dialysis organizations (SDOs) was…”
Get more information